In Brief: Angeion
This article was originally published in The Gray Sheet
Executive Summary
Angeion: Company gains investigational device exemption for clinical studies of its Model 2020 and 2022 implantable cardioverter defibrillators at 35 centers in the U.S. and plans to commence U.S. trials "in a few weeks," company Chairman and CEO Whitney McFarlin reports at a Feb. 5 session of the Piper Jaffray medical device conference in New York City. The 2020, with a weight of 89 grams and volume of 47 cc, is 25% smaller than the firm's 110 gram, 60 cc Sentinel series ICD, for which a June 1997 premarket approval application is pending at FDA ("The Gray Sheet" June 23, In Brief). The 2020 family and Sentinel feature small cap, Tuned biphasic waveform and the ASEC II dual battery system. The 2020 family also offers 60 minutes of electrogram storage. The 2022 model is specifically intended as a replacement device compatible with other manufacturers' lead systems. The devices will be marketed in the U.S. through Angellan Medical Systems' 100-person direct sales force. Angellan is a 50/50 joint venture established by Angeion and Synthelabo's Ela Medical unit. McFarlin also tells investors that Angeion is developing a model 2030 single chamber ICD and a 2100 dual-chamber ICD, for which clinical trials will begin in 1998 and 1999, respectively...
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.